WuXi PharmaTech Announces Third Quarter 20...( Third Quarter 2007 Net Inco...),Health

Third Quarter 2007 Net Income Grows 205% Year-Over-Year

SHANGHAI, China, Nov. 12 /Xinhua-PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX) ("WuXi PharmaTech" or "the Company"), the leading China-based pharmaceutical and biotechnology research and development outsourcing company, today announced its selected unaudited financial results for the third quarter ended September 30, 2007.

Third Quarter 2007 Highlights:

-- Total net revenues increased 77.8% over the third quarter of 2006 to

$34.0 million.

-- Net revenue from laboratory services increased 59.1% over the third

quarter of 2006 to $26.7 million.

-- Net revenue from research manufacturing increased 211.8% over the

third quarter of 2006 to $7.3 million.

-- Net income increased 205.4% over the third quarter of 2006 to $8.6

million.

-- Diluted earnings per American Depositary Share ("ADS") for the third

quarter of 2007 were $0.12. Diluted earnings per ADS excluding share-

based compensation expenses (non-GAAP) for the third quarter of 2007

were $0.15.

Commenting on the third quarter results, Dr. Ge Li, Chairman and Chief Executive Officer of WuXi PharmaTech commented, "I am pleased to report another quarter of strong financial and operational performance as we continue to grow our business by focusing on providing high-quality services to our customers. Our results reflect increased revenue contribution from our existing customers as well as from new customers. During the third quarter, we opened our new formulation development laboratory. In September we started the construction of our GLP (Good Laboratory Practice) drug safety eval
'/>"/>